Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Gerlach

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
CNS Drugs|September 6, 2024
Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry StudyDaniel Kreiter, Tomas Kalincik, Raymond Hupperts, et al.
Frontiers in Neuroscience|November 14, 2025
Leveraging hand-crafted radiomics on multicenter FLAIR MRI for predicting disability worsening in people with multiple sclerosisHamza Khan, Henry C Woodruff, Diana L Giraldo, et al.
Journal of Neurology|May 7, 2026
The practice effect of smartphone-derived cognitive processing speed assessments as a proxy of cognitive functioning in multiple sclerosisDaan J de Jong, Pam C G Molenaar, Vera Verhoef, et al.
Neurology|July 1, 2021
Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple SclerosisIzanne Roos, Emmanuelle Leray, Romain Casey, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Risk of secondary progressive multiple sclerosis after early worsening of disabilityWinston Dzau, Sifat Sharmin, Francesco Patti, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2022
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registryTim Spelman, Serkan Ozakbas, Raed Alroughani, et al.
Neurodegenerative Disease Management|June 8, 2023
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registryTim Spelman, Serkan Ozakbas, Raed Alroughani, et al.
CNS Drugs|February 14, 2025
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational StudyJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2025
Managing reactivation of multiple sclerosis during treatment with natalizumabNathaniel Lizak, Sifat Sharmin, Dana Horáková, et al.
Therapeutic Advances in Neurological Disorders|April 1, 2026
Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registryAndrea Surcinelli, Tomas Kalincik, Izanne Roos, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
CNS Drugs|September 6, 2024
Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry StudyDaniel Kreiter, Tomas Kalincik, Raymond Hupperts, et al.
Frontiers in Neuroscience|November 14, 2025
Leveraging hand-crafted radiomics on multicenter FLAIR MRI for predicting disability worsening in people with multiple sclerosisHamza Khan, Henry C Woodruff, Diana L Giraldo, et al.
Journal of Neurology|May 7, 2026
The practice effect of smartphone-derived cognitive processing speed assessments as a proxy of cognitive functioning in multiple sclerosisDaan J de Jong, Pam C G Molenaar, Vera Verhoef, et al.
Neurology|July 1, 2021
Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple SclerosisIzanne Roos, Emmanuelle Leray, Romain Casey, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Risk of secondary progressive multiple sclerosis after early worsening of disabilityWinston Dzau, Sifat Sharmin, Francesco Patti, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2022
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registryTim Spelman, Serkan Ozakbas, Raed Alroughani, et al.
Neurodegenerative Disease Management|June 8, 2023
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registryTim Spelman, Serkan Ozakbas, Raed Alroughani, et al.
CNS Drugs|February 14, 2025
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational StudyJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2025
Managing reactivation of multiple sclerosis during treatment with natalizumabNathaniel Lizak, Sifat Sharmin, Dana Horáková, et al.
Therapeutic Advances in Neurological Disorders|April 1, 2026
Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registryAndrea Surcinelli, Tomas Kalincik, Izanne Roos, et al.
Pageof 6